<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19870">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01721811</url>
  </required_header>
  <id_info>
    <org_study_id>Klefter2</org_study_id>
    <nct_id>NCT01721811</nct_id>
  </id_info>
  <brief_title>Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism</brief_title>
  <official_title>Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate how the retina adapts to different metabolic
      challenges, e.g. chronic systemic hypoxia, hyperglycemia, special training conditions or
      diets as well as transient changes in the content of oxygen and glucose in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Retinal vessel diameters during hyperoxia</measure>
    <time_frame>Before hyperoxia, after 15 minutes of hyperoxia, 30 minutes after ending hyperoxia</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal vessel diameters before, during and after hyperoxic stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal perfusion velocities during hyperoxia</measure>
    <time_frame>Before hyperoxia, after 15 minutes of hyperoxia, 30 minutes after ending hyperoxia</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal perfusion velocities before, during and after hyperoxic stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal oximetry during hyperoxia</measure>
    <time_frame>Before hyperoxia, after 15 minutes of hyperoxia, 30 minutes after ending hyperoxia</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal oximetry status before, during and after hyperoxic stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal vessel diameters during hyperglycemia</measure>
    <time_frame>Before glucose ingestion, every 30 minutes for 3 hours following oral glucose load</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal vessel diameters before, during and after hyperglycemic stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal perfusion during hyperglycemia</measure>
    <time_frame>Before glucose ingestion, every 30 minutes for 3 hours following oral glucose load</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal perfusion velocities before, during and after hyperglycemic stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal oximetry during hyperglycemia</measure>
    <time_frame>Before glucose ingestion, every 30 minutes for 3 hours following oral glucose load</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of retinal oximetry status before, during and after hyperglycemic stimulation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy Individuals</condition>
  <condition>Patients With Diabetes.</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy study participanats</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperoxia</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Diabetes</arm_group_label>
    <other_name>Hyperoxia is achieved by short-term pure oxygen breathing.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Diabetes</arm_group_label>
    <other_name>Standardised oral glucose load.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy individuals

        Inclusion Criteria:

          -  Healthy volunteers.

          -  No known systemic or ocular disease.

        Exclusion Criteria:

          -  Any systemic or ocular disease.

        Patients with diabetes

        Inclusion criteria:

          -  Diabetes mellitus

          -  No intraocular disease other than conditions attributable to diabetes.

        Exclusion criteria:

          -  Intraocular disease other than conditions attributable to diabetes.

          -  Systemic conditions which might contraindicate hyperoxic stimulation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Klefter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Larsen, Professor, DMSci</last_name>
    <role>Study Director</role>
    <affiliation>Glostrup UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Klefter, MD</last_name>
    <phone>+45 38 63 48 18</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Glostrup University Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Klefter, MD</last_name>
      <phone>+45 38 63 48 18</phone>
    </contact>
    <contact_backup>
      <last_name>Michael Larsen, Professor, DMSci</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 2, 2012</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Oliver Niels Klefter</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
